StockNow
Calendar
Log in
U.S. Markets

European Commission has approved Merck's (MRK) Keytruda plus Padcev, as perioperative treatment

StockNow breaking-news AI analysis

A 2026-10-21 breaking-news headline reports European Commission approval of Merck’s Keytruda plus Padcev as perioperative treatment; no further details are available in the record.

1 stocks
MRKMerck & Co., Inc.$147.30Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Pakistan Army Chief Munir, in his meeting with Iranian officials, brought with him the "final warning" from the United States, which calls on Iran to submit to the American demand for concessions on the nuclear issue before taking any other steps

Politics

Iran's Secretary of Supreme National Security Council Rezaei informed Pakistan's Army Chief Munir of Iran's explicit rejection of the American demands, reports Al Hadath

Geopolitics

Iran's Foreign Minister Araghchi says they are ready for diplomacy, but will defend themselves, FT reports; US has shown no willingness to reach an understanding, little reason to expect progress now